Myeloma Magazine
December 14, 2023
UAMS Researcher Takes Aim at Drug-Resistant Myeloma
UAMS Myeloma Center researcher Fenghuang (Frank) Zhan, M.D., Ph.D., has spent his career in search of clues to help fight drug-resistant myeloma. His findings recently led him to establish a translational research project to beat drug-resistant myeloma for his 11-member myeloma research team, based at the UAMS Winthrop P. Rockefeller Cancer Institute. While the…
New Immune Therapies Provide Promising Advances in Myeloma Care
By Frits van Rhee, MD, Ph.D. Since the late 1990s, 16 drugs have been approved for the treatment of multiple myeloma, including proteasome inhibitors, such as bortezomib and carfilzomib, and the immunomodulatory class of agents comprising thalidomide, lenalidomide and pomalidomide. Immune therapy with the antibody daratumumab was first approved in 2015. These three classes of…
Expanding the Field: Clinical Trials Diversity Benefits Myeloma Research
Clinical trials have long been an established part of medical research. The University of Arkansas for Medical Sciences (UAMS) Myeloma Center and the Clinical Trials Office work together to create a more diverse pool of clinical trial participants in the continuing research of multiple myeloma. Samer Al Hadidi, M.D., is a driving force in this…
From the Clinical Director
It is my great pleasure to present the Winter 2023 issue of the Myeloma magazine. The landscape of myeloma care is going through an unprecedented change due to the introduction of highly effective, groundbreaking novel immunotherapies. These new therapies include the patient’s own genetically enhanced immune cells also referred to as chimeric antigen receptor (CAR) T-cells. Other…
From The Director
Outstanding research Expert clinical care Robust clinical trials Broad reach into the catchment area and across the nation These are the hallmarks of any cancer center truly committed to changing the trajectory of cancer for the better. If you have visited the Myeloma Center at the UAMS Winthrop P. Rockefeller Cancer Institute, you have seen…
Previous page